Phase 3

[키워드] 24 hour acute respiratory distress syndrome addition Administered Anakinra anti-IL-1 anti-IL-6 anti-IL-6 receptor antibody Bacterial Belgium binding blinded blockade Blood characterized chest X-ray chimeric clinical Clinical improvement Combination composed Coronavirus infection COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient CT scan death defined discharge dissemination dose drug Effectiveness element EudraCT excluded experimental arm factorial design Fungal infection hospital hospital discharge Hospitalized hospitals hypoxia hypoxic respiratory failure ICU IL-1 IL-6 IL-6 blockade IL-6 receptor interleukin 1 blockade interleukin 6 blockade Intravenous injection Invasive mechanical ventilation LDH lymphopenia mechanical ventilation non-invasive ventilation number objective on mechanical ventilation open label Open-label outcome oxygen Oxygenation paO2/fiO2 participant Participants Patient patients with COVID-19 Phase 3 primary end point protocol randomisation randomised randomised controlled trial randomization Randomized receive receptor recruited recruitment Registered response Sample size Serum ferritin siltuximab standard care Standard of care status Study protocol subcutaneous injection supplemental oxygen syndrome System systemic cytokine systemic cytokine release syndrome Tocilizumab treated Trial usual care was selected Web website
[DOI] 10.1186/s13063-020-04453-5 PMC 바로가기 [Article Type] Letter